• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ASCO: Novel Drug Safe, Promising in ALL

Article

An investigational immunotherapy was well tolerated and active in patients with acute lymphoblastic leukemia (ALL), a researcher said here.

In a small phase II study, the bi-specific antibody blinatumomab had an "exceptionally high response rate," said Max Topp, MD, of University Hospitals of Wuerzburg in Wuerzburg, Germany.

Over all doses, 72% of the study's 36 patients had a complete response or a hematological complete response within two cycles of treatment, Topp reported at the annual meeting of the American Society of Clinical Oncology. The proportion was slightly higher — 74% -- among the 23 patients who had the safest dose from the start.

Read the full story: http://hcp.lv/JLNsld

Source: MedPage Today

Related Videos
4 experts in this video
4 experts in this video
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Dr Carla Nester
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.